What is Weave?
Weave Bio is an AI-native platform company operating at the intersection of life sciences, pharmaceuticals, and biotechnology. The company's core offering, AutoIND, is designed to streamline the complex Investigational New Drug (IND) application process. By leveraging advanced AI capabilities, Weave Bio enables drug development teams to construct a living record of their therapeutic candidates, thereby driving substantial improvements in both operational efficiency and the quality of critical regulatory submissions. This innovative approach addresses significant pain points inherent in the pharma and biotech industries, positioning Weave Bio as a key player in the digital transformation of drug discovery and development.
How much funding has Weave raised?
Weave has raised a total of $30M across 2 funding rounds:
Angel/Seed
$10M
Series A
$20M
Angel/Seed (2024): $10M with participation from Innovation Endeavors and Magnetic Ventures
Series A (2025): $20M led by Magnetic Ventures, Innovation Endeavors, Tmv, Serrado Capital, The Character Group, and US Venture Partners
Key Investors in Weave
Magnetic Ventures
Magnetic Ventures is a female-founded venture capital firm that partners with early-stage founders to leverage AI, machine learning, and next-gen biotech for healthcare innovation. The firm focuses on deep technology to transform life sciences, providing not just capital but also hands-on support throughout the company lifecycle.
Innovation Endeavors
Innovation Endeavors is an early-stage venture capital firm that invests in visionary founders, transformational technologies and emergent ecosystems. The firm's central investment thesis, the Super Evolution, combines data, leading-edge computation, and advanced engineering to transform industries, from agriculture and logistics to life sciences, transportation and more.
Tmv
Tmv is a company that operates in the Venture Capital & Private Equity industry. It employs 10to19 people and has 1Mto5M of revenue. The company is headquartered in New York City, New York.
What's next for Weave?
The recent major strategic investment in Weave Bio's Series A round signals a critical growth phase for the company. This capital infusion is expected to fuel the scaling of its AI-enabled platform, further enhancing its capabilities in streamlining drug development pipelines. With a focus on enterprise-level solutions for the pharma and biotech sectors, Weave Bio is poised to expand its market reach and solidify its position as a leader in AI-driven life sciences innovation. Future developments will likely involve deeper integration of its technology into existing industry workflows and continued advancements in its AI models to address evolving regulatory and scientific challenges.
See full Weave company page
